Quick Answer
TScan Therapeutics, Inc. reported Stockholders Equity of $123.12 million for fiscal year 2025.
TScan Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $123.12M | -48.9% |
| 2024 | $240.97M | +59.7% |
| 2023 | $150.87M | +51.7% |
| 2022 | $99.43M | -38.2% |
| 2021 | $160.78M | +478.6% |
| 2020 | -$42.46M | -147.8% |
| 2019 | -$17.14M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $144.02M | -37.1% | -18.5% |
| June 30, 2025 | $176.71M | -30.8% | -15.9% |
| March 31, 2025 | $210.20M | +70.9% | -12.8% |
| December 31, 2024 | $240.97M | +59.7% | +5.2% |
| September 30, 2024 | $229.09M | +35.6% | -10.2% |
| June 30, 2024 | $255.22M | +33.9% | +107.6% |
| March 31, 2024 | $122.97M | +57.6% | -18.5% |
| December 31, 2023 | $150.87M | +51.7% | -10.7% |
- TScan Therapeutics, Inc. showed a decrease of -48.9% in Stockholders Equity compared to the prior fiscal year.
- Over the 2019–2025 period, TScan Therapeutics, Inc.’s stockholders equity has grown by 818.4% (from -$17.14 million to $123.12 million).
- The most recent figure is from TScan Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 4, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: